Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer
Arvind Arora, Tarek Mohamed Ahmed Abdel-Fatah, Devika Agarwal et al. · Molecular Cancer Therapeutics · 2015
Bloom syndrome helicase (BLM) has key roles in homologous recombination repair, telomere maintenance, and DNA replication. Germ-line mutations in the BLM gene causes Bloom syndrome, a rare disorder characterized by premature aging and predisposition to multiple cancers, including breast cancer. The clinicopathologic significance of BLM in sporadic breast cancers is unknown. We investigated BLM mRNA expression in the Molecular Taxonomy of Breast Cancer International Consortium cohort (n = 1,950) and validated in an external dataset of 2,413 tumors. BLM protein level was evaluated in the Nottingham Tenovus series comprising 1,650 breast tumors. BLM mRNA overexpression was significantly associated with high histologic grade, larger tumor size, estrogen receptor-negative (ER(-)), progesterone receptor-negative (PR(-)), and triple-negative phenotypes (ps < 0.0001). BLM mRNA overexpression was also linked to aggressive molecular phenotypes, including PAM50.Her2 (P < 0.0001), PAM50.Basal (P < 0.0001), and PAM50.LumB (P < 0.0001) and Genufu subtype (ER(+)/Her2(-)/high proliferation; P < 0.0001). PAM50.LumA tumors and Genufu subtype (ER(+)/Her2(-)/low proliferation) were more likely to express low levels of BLM mRNA (ps < 0.0001). Integrative molecular clusters (intClust) intClust.1 (P < 0.0001), intClust.5 (P < 0.0001), intClust.9 (P < 0.0001), and intClust.10 (P < 0.0001) were also more likely in tumors with high BLM mRNA expression. BLM mRNA overexpression was associated with poor breast cancer-specific survival (BCSS; ps < 0.000001). At the protein level, altered subcellular localization with high cytoplasmic BLM and low nuclear BLM was linked to aggressive phenotypes. In multivariate analysis, BLM mRNA and BLM protein levels independently influenced BCSS. This is the first and the largest study to provide evidence that BLM is a promising biomarker in breast cancer.
Cited by 52 works. doi:10.1158/1535-7163.mct-14-0939
Authors
- Arvind Arora
- Tarek Mohamed Ahmed Abdel-Fatah
- Devika Agarwal
- Rachel E. Doherty
- Paul M. Moseley
- Mohammed A. Aleskandarany
- Andrew R. Green
- Graham Ball
- Alaa T. Alshareeda
- Emad A. Rakha
- Stephen Y.T. Chan
- Ian Ogilvie Ellis
- Srinivasan Madhusudan
References
- A Simple Sequentially Rejective Multiple Test Procedure
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
- BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures
- RecQ helicases: multifunctional genome caretakers
- Regulation and Localization of the Bloom Syndrome Protein in Response to DNA Damage
- Human RecQ Helicases in DNA Repair, Recombination, and Replication
- Mechanisms of RecQ helicases in pathways of DNA metabolism and maintenance of genomic stability
- Roles of the Bloom's syndrome helicase in the maintenance of genome stability